ArticleAnimal models and experimental medicine2026
Adenosine monophosphate-activated protein kinase activation is associated with suppression of NLRP3 inflammasome-mediated neuroinflammation in a weight-drop model of traumatic brain injury in Sprague-Dawley rats.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTraumatic brain injury (TBI) disrupts adenosine monophosphate-activated protein kinase (AMPK) signaling, impairs energy homeostasis, activates inflammatory pathways, and triggers neuroinflammation. AMPK activators such as metformin (MET), quercetin (QUE), resveratrol (RES), cinnamaldehyde (CIN), and berberine (BER) exhibit anti-inflammatory and neuroprotective properties. However, their role in modulating the nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome in TBI-induced neuroinflammation remains unclear. This study investigated the neuroprotective effects of AMPK activators in the weight-drop model of TBI, focusing on suppression of the NLRP3 inflammasome.
methodsRats received an intraperitoneal administration of AMPK activators-MET (100 mg/kg), QUE (15 mg/kg), RES (25 mg/kg), CIN (25 mg/kg), or BER (50 mg/kg)-from days -3 to 17. TBI was induced on day 1 using the weight-drop method (240 g from 1.5 m). Cognitive performance was evaluated using the novel object recognition test and Morris water maze. Neuroinflammatory markers, including nuclear factor kappa B (NF-κB), NLRP3, pro-caspase-1, interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and microglial polarization markers (CD86 and CD206), were assessed using Western blotting and enzyme-linked immunosorbent assay (ELISA). Oxidative stress and histopathological changes were also examined.
resultsTBI resulted in cognitive impairment, oxidative stress, and neuronal damage; reduced p-AMPK/AMPK ratio; decreased CD206 levels; and elevated the levels of NF-κB, CD86, TNF-α, and NLRP3 inflammasome components (NLRP3, pro-caspase-1, and IL-1β). Pretreatment with AMPK activators significantly improved cognitive deficits, attenuated oxidative stress and neuroinflammation, restored p-AMPK/AMPK ratio, promoted anti-inflammatory effects, and suppressed NLRP3 inflammasome activation.
conclusionAMPK activators exhibited neuroprotection in TBI by improving cognition and regulating oxidative stress, microglial activation, and NLRP3-mediated neuroinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.